{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T04:03:28Z","timestamp":1768449808548,"version":"3.49.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T00:00:00Z","timestamp":1711238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T00:00:00Z","timestamp":1711238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["CRG\/2020\/002932"],"award-info":[{"award-number":["CRG\/2020\/002932"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s11030-024-10824-w","type":"journal-article","created":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T05:01:22Z","timestamp":1711256482000},"page":"4403-4424","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Exploring host epigenetic enzymes as targeted therapies for visceral leishmaniasis: in silico design and in vitro efficacy of KDM6B and ASH1L inhibitors"],"prefix":"10.1007","volume":"28","author":[{"given":"Mukul","family":"Dutta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tooba","family":"Qamar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Unnati","family":"Kushavah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Imran","family":"Siddiqi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanta","family":"Kar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,24]]},"reference":[{"key":"10824_CR1","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(18)31204-2","volume":"392","author":"S Burza","year":"2018","unstructured":"Burza S, Croft SL, Boelaert M (2018) Leishmaniasis. Lancet 392:951\u2013970. https:\/\/doi.org\/10.1016\/S0140-6736(18)31204-2","journal-title":"Lancet"},{"key":"10824_CR2","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1017\/S0031182016002523","volume":"145","author":"SRB Uliana","year":"2018","unstructured":"Uliana SRB, Trinconi CT, Coelho AC (2018) Chemotherapy of leishmaniasis: present challenges. Parasitology 145:464\u2013480. https:\/\/doi.org\/10.1017\/S0031182016002523","journal-title":"Parasitology"},{"key":"10824_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.660183","volume":"12","author":"FO Novais","year":"2021","unstructured":"Novais FO, Amorim CF, Scott P (2021) Host-directed therapies for cutaneous leishmaniasis. Front Immunol 12:660183. https:\/\/doi.org\/10.3389\/fimmu.2021.660183","journal-title":"Front Immunol"},{"key":"10824_CR4","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/S1473-3099(10)70011-6","volume":"10","author":"J van Griensven","year":"2010","unstructured":"van Griensven J, Balasegaram M, Meheus F et al (2010) Combination therapy for visceral leishmaniasis. Lancet Infect Dis 10:184\u2013194. https:\/\/doi.org\/10.1016\/S1473-3099(10)70011-6","journal-title":"Lancet Infect Dis"},{"key":"10824_CR5","doi-asserted-by":"publisher","DOI":"10.1128\/Spectrum.01018-21","volume":"9","author":"JE Martinez-Hernandez","year":"2021","unstructured":"Martinez-Hernandez JE, Hammoud Z, de Sousa AM et al (2021) Network-based approaches reveal potential therapeutic targets for host-directed antileishmanial therapy driving drug repurposing. Microbiol Spectr 9:e0101821. https:\/\/doi.org\/10.1128\/Spectrum.01018-21","journal-title":"Microbiol Spectr"},{"key":"10824_CR6","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1002\/eji.201141792","volume":"41","author":"O Takeuch","year":"2011","unstructured":"Takeuch O, Akira S (2011) Epigenetic control of macrophage polarization. Eur J Immunol 41:2490\u20132493. https:\/\/doi.org\/10.1002\/eji.201141792","journal-title":"Eur J Immunol"},{"key":"10824_CR7","doi-asserted-by":"publisher","first-page":"492","DOI":"10.3389\/fimmu.2019.00492","volume":"10","author":"F Afrin","year":"2019","unstructured":"Afrin F, Khan I, Hemeg HA (2019) Leishmania-host interactions-an epigenetic paradigm. Front Immunol 10:492. https:\/\/doi.org\/10.3389\/fimmu.2019.00492","journal-title":"Front Immunol"},{"key":"10824_CR8","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nrg3173","volume":"13","author":"EL Greer","year":"2012","unstructured":"Greer EL, Shi Y (2012) Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet 13:343\u2013357. https:\/\/doi.org\/10.1038\/nrg3173","journal-title":"Nat Rev Genet"},{"key":"10824_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/mog2.59","volume":"3","author":"L Tao","year":"2024","unstructured":"Tao L, Zhou Y, Luo Y et al (2024) Epigenetic regulation in cancer therapy: From mechanisms to clinical advances. MedComm Oncol 3:e59. https:\/\/doi.org\/10.1002\/mog2.59","journal-title":"MedComm Oncol"},{"key":"10824_CR10","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1038\/s41467-021-23152-6","volume":"12","author":"DS Rogawski","year":"2021","unstructured":"Rogawski DS, Deng J, Li H et al (2021) Discovery of first-in-class inhibitors of ASH1L histone methyltransferase with anti-leukemic activity. Nat Commun 12:2792. https:\/\/doi.org\/10.1038\/s41467-021-23152-6","journal-title":"Nat Commun"},{"key":"10824_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.818070","volume":"13","author":"Z Zhao","year":"2022","unstructured":"Zhao Z, Zhang Y, Gao D et al (2022) Inhibition of histone H3 lysine-27 demethylase activity relieves rheumatoid arthritis symptoms via repression of il6 transcription in macrophages. Front Immunol 13:818070. https:\/\/doi.org\/10.3389\/fimmu.2022.818070","journal-title":"Front Immunol"},{"key":"10824_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.680633","volume":"12","author":"G Punnia-Moorthy","year":"2021","unstructured":"Punnia-Moorthy G, Hersey P, Emran AA, Tiffen J (2021) Lysine demethylases: promising drug targets in melanoma and other cancers. Front Genet 12:680633. https:\/\/doi.org\/10.3389\/fgene.2021.680633","journal-title":"Front Genet"},{"key":"10824_CR13","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.3390\/ijms18071414","volume":"18","author":"T Eckschlager","year":"2017","unstructured":"Eckschlager T, Plch J, Stiborova M, Hrabeta J (2017) Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci 18:1414. https:\/\/doi.org\/10.3390\/ijms18071414","journal-title":"Int J Mol Sci"},{"key":"10824_CR14","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3390\/genes12020208","volume":"12","author":"A Majchrzak-Celi\u0144ska","year":"2021","unstructured":"Majchrzak-Celi\u0144ska A, Warych A, Szoszkiewicz M (2021) Novel approaches to epigenetic therapies: from drug combinations to epigenetic editing. Genes (Basel) 12:208. https:\/\/doi.org\/10.3390\/genes12020208","journal-title":"Genes (Basel)"},{"key":"10824_CR15","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3390\/ph15060687","volume":"15","author":"LS Prieto C\u00e1rdenas","year":"2022","unstructured":"Prieto C\u00e1rdenas LS, Arias Soler KA, Nossa Gonz\u00e1lez DL et al (2022) In silico antiprotozoal evaluation of 1,4-naphthoquinone derivatives against chagas and leishmaniasis diseases using QSAR, molecular docking, and ADME approaches. Pharmaceuticals (Basel) 15:687. https:\/\/doi.org\/10.3390\/ph15060687","journal-title":"Pharmaceuticals (Basel)"},{"key":"10824_CR16","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s13148-021-01154-x","volume":"13","author":"C Hu","year":"2021","unstructured":"Hu C, Liu X, Zeng Y et al (2021) DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application. Clin Epigenetics 13:166. https:\/\/doi.org\/10.1186\/s13148-021-01154-x","journal-title":"Clin Epigenetics"},{"key":"10824_CR17","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.4049\/jimmunol.1900251","volume":"204","author":"N Parmar","year":"2020","unstructured":"Parmar N, Chandrakar P, Kar S (2020) Leishmania donovani subverts host immune response by epigenetic reprogramming of macrophage M(Lipopolysaccharides + IFN-\u03b3)\/M(IL-10) polarization. J Immunol 204:2762\u20132778. https:\/\/doi.org\/10.4049\/jimmunol.1900251","journal-title":"J Immunol"},{"key":"10824_CR18","doi-asserted-by":"publisher","first-page":"D115","DOI":"10.1093\/nar\/gkh131","volume":"32","author":"R Apweiler","year":"2004","unstructured":"Apweiler R, Bairoch A, Wu CH et al (2004) UniProt: the universal protein knowledgebase. Nucleic Acids Res 32:D115\u2013D119. https:\/\/doi.org\/10.1093\/nar\/gkh131","journal-title":"Nucleic Acids Res"},{"key":"10824_CR19","doi-asserted-by":"publisher","unstructured":"McGinnis S, Madden TL (2004) BLAST: at the core of a powerful and diverse set of sequence analysis tools. Nucleic Acids Research 32: W20\u2013W25. https:\/\/doi.org\/10.1093\/nar\/gkh435","DOI":"10.1093\/nar\/gkh435"},{"key":"10824_CR20","doi-asserted-by":"publisher","unstructured":"Boratyn GM, Camacho C, Cooper PS, et al (2013) BLAST: a more efficient report with usability improvements. Nucleic Acids Research 41: W29\u2013W33. https:\/\/doi.org\/10.1093\/nar\/gkt282","DOI":"10.1093\/nar\/gkt282"},{"key":"10824_CR21","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/pro.3730","volume":"29","author":"DS Goodsell","year":"2020","unstructured":"Goodsell DS, Zardecki C, Di Costanzo L et al (2020) RCSB protein data bank: enabling biomedical research and drug discovery. Protein Sci 29:52\u201365. https:\/\/doi.org\/10.1002\/pro.3730","journal-title":"Protein Sci"},{"key":"10824_CR22","first-page":"259","volume-title":"Annual reports in medicinal chemistry","author":"M Jacobson","year":"2004","unstructured":"Jacobson M, Sali A (2004) Comparative protein structure modeling and its applications to drug discovery. Annual reports in medicinal chemistry. Elsevier, pp 259\u2013276"},{"key":"10824_CR23","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1110\/ps.062416606","volume":"15","author":"MY Shen","year":"2006","unstructured":"Shen MY, Sali A (2006) Statistical potential for assessment and prediction of protein structures. Protein Sci 15:2507\u20132524. https:\/\/doi.org\/10.1110\/ps.062416606","journal-title":"Protein Sci"},{"key":"10824_CR24","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1093\/bioinformatics\/18.11.1548","volume":"18","author":"SS Sheik","year":"2002","unstructured":"Sheik SS, Sundararajan P, Hussain ASZ, Sekar K (2002) Ramachandran plot on the web. Bioinformatics 18:1548\u20131549. https:\/\/doi.org\/10.1093\/bioinformatics\/18.11.1548","journal-title":"Bioinformatics"},{"key":"10824_CR25","doi-asserted-by":"publisher","unstructured":"Hollingsworth SA, Karplus PA (2010) A fresh look at the Ramachandran plot and the occurrence of standard structures in proteins. BioMolecular Concepts 1:271\u2013283. https:\/\/doi.org\/10.1515\/bmc.2010.022","DOI":"10.1515\/bmc.2010.022"},{"key":"10824_CR26","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","volume":"27","author":"G Madhavi Sastry","year":"2013","unstructured":"Madhavi Sastry G, Adzhigirey M, Day T et al (2013) Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des 27:221\u2013234. https:\/\/doi.org\/10.1007\/s10822-013-9644-8","journal-title":"J Comput Aided Mol Des"},{"key":"10824_CR27","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/nature11262","volume":"488","author":"L Kruidenier","year":"2012","unstructured":"Kruidenier L, Chung C, Cheng Z et al (2012) A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 488:404\u2013408. https:\/\/doi.org\/10.1038\/nature11262","journal-title":"Nature"},{"key":"10824_CR28","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1016\/j.ejmech.2006.07.017","volume":"41","author":"C Michaux","year":"2006","unstructured":"Michaux C, De Leval X, Jul\u00e9mont F et al (2006) Structure-based pharmacophore of COX-2 selective inhibitors and identification of original lead compounds from 3D database searching method. Eur J Med Chem 41:1446\u20131455. https:\/\/doi.org\/10.1016\/j.ejmech.2006.07.017","journal-title":"Eur J Med Chem"},{"key":"10824_CR29","doi-asserted-by":"publisher","first-page":"140","DOI":"10.22159\/ajpcr.2017.v10i5.17157","volume":"10","author":"B Devi","year":"2017","unstructured":"Devi B, Rajagopal K, Elizabeth E (2017) Pharmacophoric screening of various endophytic fungal metabolites. Asian J Pharm Clin Res 10:140. https:\/\/doi.org\/10.22159\/ajpcr.2017.v10i5.17157","journal-title":"Asian J Pharm Clin Res"},{"key":"10824_CR30","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00894-023-05586-5","volume":"29","author":"R Ribeiro","year":"2023","unstructured":"Ribeiro R, Botelho FD, Pinto AMV et al (2023) Molecular modeling study of natural products as potential bioactive compounds against SARS-CoV-2. J Mol Model 29:183. https:\/\/doi.org\/10.1007\/s00894-023-05586-5","journal-title":"J Mol Model"},{"key":"10824_CR31","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s10822-006-9087-6","volume":"20","author":"SL Dixon","year":"2006","unstructured":"Dixon SL, Smondyrev AM, Knoll EH et al (2006) PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J Comput Aided Mol Des 20:647\u2013671. https:\/\/doi.org\/10.1007\/s10822-006-9087-6","journal-title":"J Comput Aided Mol Des"},{"key":"10824_CR32","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1186\/s13287-020-02051-5","volume":"11","author":"C Pribadi","year":"2020","unstructured":"Pribadi C, Camp E, Cakouros D et al (2020) Pharmacological targeting of KDM6A and KDM6B, as a novel therapeutic strategy for treating craniosynostosis in Saethre-Chotzen syndrome. Stem Cell Res Ther 11:529. https:\/\/doi.org\/10.1186\/s13287-020-02051-5","journal-title":"Stem Cell Res Ther"},{"key":"10824_CR33","doi-asserted-by":"publisher","first-page":"9407","DOI":"10.3390\/ijms23169407","volume":"23","author":"PH Hung","year":"2022","unstructured":"Hung PH, Hsu YC, Chen TH et al (2022) The histone demethylase inhibitor GSK-J4 Is a therapeutic target for the kidney fibrosis of diabetic kidney disease via DKK1 modulation. Int J Mol Sci 23:9407. https:\/\/doi.org\/10.3390\/ijms23169407","journal-title":"Int J Mol Sci"},{"key":"10824_CR34","doi-asserted-by":"publisher","first-page":"174","DOI":"10.5530\/jyp.2022.14.33","volume":"14","author":"SB Bai","year":"2022","unstructured":"Bai SB, Geethavani M, Ramakrishna C (2022) Synthesis characterization and molinspiration analysis, anti-bacterial activity of novel 2,4,6-tri substituted pyrimidines. J Young Pharm 14:174\u2013178. https:\/\/doi.org\/10.5530\/jyp.2022.14.33","journal-title":"J Young Pharm"},{"key":"10824_CR35","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/2193-1801-2-353","volume":"2","author":"F Ntie-Kang","year":"2013","unstructured":"Ntie-Kang F (2013) An in silico evaluation of the ADMET profile of the StreptomeDB database. Springerplus 2:353. https:\/\/doi.org\/10.1186\/2193-1801-2-353","journal-title":"Springerplus"},{"key":"10824_CR36","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.str.2019.01.015","volume":"27","author":"P Hou","year":"2019","unstructured":"Hou P, Huang C, Liu C-P et al (2019) Structural insights into stimulation of Ash1L\u2019s H3K36 methyltransferase activity through Mrg15 binding. Structure 27:837\u2013845.e3. https:\/\/doi.org\/10.1016\/j.str.2019.01.015","journal-title":"Structure"},{"key":"10824_CR37","doi-asserted-by":"publisher","first-page":"6177","DOI":"10.1021\/jm051256o","volume":"49","author":"RA Friesner","year":"2006","unstructured":"Friesner RA, Murphy RB, Repasky MP et al (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein\u2212ligand complexes. J Med Chem 49:6177\u20136196. https:\/\/doi.org\/10.1021\/jm051256o","journal-title":"J Med Chem"},{"key":"10824_CR38","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1021\/acs.jmedchem.6b01447","volume":"60","author":"D Anand","year":"2017","unstructured":"Anand D, Yadav PK, Patel OPS et al (2017) Antileishmanial activity of pyrazolopyridine derivatives and their potential as an adjunct therapy with miltefosine. J Med Chem 60:1041\u20131059. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b01447","journal-title":"J Med Chem"},{"key":"10824_CR39","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/0001-706x(93)90083-n","volume":"55","author":"W Huber","year":"1993","unstructured":"Huber W, Koella JC (1993) A comparison of three methods of estimating EC50 in studies of drug resistance of malaria parasites. Acta Trop 55:257\u2013261. https:\/\/doi.org\/10.1016\/0001-706x(93)90083-n","journal-title":"Acta Trop"},{"key":"10824_CR40","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1128\/AAC.48.11.4097-4102.2004","volume":"48","author":"QL Fivelman","year":"2004","unstructured":"Fivelman QL, Adagu IS, Warhurst DC (2004) Modified fixed-ratio isobologram method for studying in vitro interactions between atovaquone and proguanil or dihydroartemisinin against drug-resistant strains of Plasmodium falciparum. Antimicrob Agents Chemother 48:4097\u20134102. https:\/\/doi.org\/10.1128\/AAC.48.11.4097-4102.2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10824_CR41","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.str.2019.04.012","volume":"27","author":"I De","year":"2019","unstructured":"De I, M\u00fcller CW (2019) Unleashing the power of ASH1L methyltransferase. Structure 27:727\u2013728. https:\/\/doi.org\/10.1016\/j.str.2019.04.012","journal-title":"Structure"},{"key":"10824_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.906807","volume":"12","author":"M Yu","year":"2022","unstructured":"Yu M, Jia Y, Ma Z et al (2022) Structural insight into ASH1L PHD finger recognizing methylated histone H3K4 and promoting cell growth in prostate cancer. Front Oncol 12:906807. https:\/\/doi.org\/10.3389\/fonc.2022.906807","journal-title":"Front Oncol"},{"key":"10824_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29304","volume":"68","author":"RT Kurmasheva","year":"2021","unstructured":"Kurmasheva RT, Erickson SW, Han R et al (2021) In vivo evaluation of the lysine-specific demethylase (KDM1A\/LSD1) inhibitor SP-2577 (Seclidemstat) against pediatric sarcoma preclinical models: a report from the pediatric preclinical testing consortium (PPTC). Pediatr Blood Cancer 68:e29304. https:\/\/doi.org\/10.1002\/pbc.29304","journal-title":"Pediatr Blood Cancer"},{"key":"10824_CR44","doi-asserted-by":"publisher","first-page":"TPS11567","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS11567","volume":"38","author":"DR Reed","year":"2020","unstructured":"Reed DR, Mascarenhas L, Meyers PA et al (2020) A phase I\/II clinical trial of the reversible LSD1 inhibitor, seclidemstat, in patients with relapsed\/refractory Ewing sarcoma. JCO 38:TPS11567\u2013TPS11567. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.TPS11567","journal-title":"JCO"},{"key":"10824_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmgm.2019.107512","volume":"96","author":"S Ahmad","year":"2020","unstructured":"Ahmad S, Bhagwati S, Kumar S et al (2020) Molecular modeling assisted identification and biological evaluation of potent cathepsin S inhibitors. J Mol Graph Model 96:107512. https:\/\/doi.org\/10.1016\/j.jmgm.2019.107512","journal-title":"J Mol Graph Model"},{"key":"10824_CR46","doi-asserted-by":"publisher","first-page":"11225","DOI":"10.1021\/ja9621760","volume":"118","author":"WL Jorgensen","year":"1996","unstructured":"Jorgensen WL, Maxwell DS, Tirado-Rives J (1996) Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc 118:11225\u201311236. https:\/\/doi.org\/10.1021\/ja9621760","journal-title":"J Am Chem Soc"},{"key":"10824_CR47","doi-asserted-by":"publisher","first-page":"4956","DOI":"10.1080\/07391102.2019.1691659","volume":"38","author":"S Bhagwati","year":"2020","unstructured":"Bhagwati S, Siddiqi MI (2020) Identification of potential soluble epoxide hydrolase (sEH) inhibitors by ligand-based pharmacophore model and biological evaluation. J Biomol Struct Dyn 38:4956\u20134966. https:\/\/doi.org\/10.1080\/07391102.2019.1691659","journal-title":"J Biomol Struct Dyn"},{"key":"10824_CR48","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3389\/fcimb.2019.00229","volume":"9","author":"KM Rebello","year":"2019","unstructured":"Rebello KM, Andrade-Neto VV, Gomes CRB et al (2019) Miltefosine-lopinavir combination therapy against Leishmania infantum infection: in vitro and in vivo approaches. Front Cell Infect Microbiol 9:229. https:\/\/doi.org\/10.3389\/fcimb.2019.00229","journal-title":"Front Cell Infect Microbiol"},{"key":"10824_CR49","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1021\/acs.jnatprod.8b00356","volume":"81","author":"YSS Emiliano","year":"2018","unstructured":"Emiliano YSS, Almeida-Amaral EE (2018) Efficacy of apigenin and miltefosine combination therapy against experimental Cutaneous Leishmaniasis. J Nat Prod 81:1910\u20131913. https:\/\/doi.org\/10.1021\/acs.jnatprod.8b00356","journal-title":"J Nat Prod"},{"key":"10824_CR50","first-page":"93","volume":"41","author":"MC Berenbaum","year":"1989","unstructured":"Berenbaum MC (1989) What is synergy? Pharmacol Rev 41:93\u2013141","journal-title":"Pharmacol Rev"},{"key":"10824_CR51","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13071-020-4000-z","volume":"13","author":"J Lobo-Silva","year":"2020","unstructured":"Lobo-Silva J, Cabral FJ, Amaral MS et al (2020) The antischistosomal potential of GSK-J4, an H3K27 demethylase inhibitor: insights from molecular modeling, transcriptomics and in vitro assays. Parasit Vectors 13:140. https:\/\/doi.org\/10.1186\/s13071-020-4000-z","journal-title":"Parasit Vectors"},{"key":"10824_CR52","doi-asserted-by":"publisher","first-page":"e01766","DOI":"10.1128\/AAC.01766-19","volume":"64","author":"M Kashif","year":"2020","unstructured":"Kashif M, Paladhi A, Singh R et al (2020) Leishmanicidal activity of an in silico-screened novel inhibitor against ascorbate peroxidase of Leishmania donovani. Antimicrob Agents Chemother 64:e01766\u2013e01819. https:\/\/doi.org\/10.1128\/AAC.01766-19","journal-title":"Antimicrob Agents Chemother"},{"key":"10824_CR53","doi-asserted-by":"publisher","first-page":"114191","DOI":"10.1016\/j.bcp.2020.114191","volume":"180","author":"L \u00c2ngelo de Souza","year":"2020","unstructured":"\u00c2ngelo de Souza L, Silva Bastos M, de Melo AJ et al (2020) Histone deacetylases inhibitors as new potential drugs against Leishmania braziliensis, the main causative agent of new world tegumentary leishmaniasis. Biochem Pharmacol 180:114191. https:\/\/doi.org\/10.1016\/j.bcp.2020.114191","journal-title":"Biochem Pharmacol"},{"key":"10824_CR54","doi-asserted-by":"publisher","first-page":"40752","DOI":"10.1038\/srep40752","volume":"7","author":"L Huang","year":"2017","unstructured":"Huang L, Jiang Y, Chen Y (2017) Predicting drug combination index and simulating the network-regulation dynamics by mathematical modeling of drug-targeted EGFR-ERK signaling pathway. Sci Rep 7:40752. https:\/\/doi.org\/10.1038\/srep40752","journal-title":"Sci Rep"},{"key":"10824_CR55","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.3389\/fphar.2019.01222","volume":"10","author":"RY Huang","year":"2019","unstructured":"Huang RY, Pei L, Liu Q et al (2019) Isobologram analysis: a comprehensive review of methodology and current research. Front Pharmacol 10:1222. https:\/\/doi.org\/10.3389\/fphar.2019.01222","journal-title":"Front Pharmacol"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-024-10824-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-024-10824-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-024-10824-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T17:07:29Z","timestamp":1734628049000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-024-10824-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,24]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10824"],"URL":"https:\/\/doi.org\/10.1007\/s11030-024-10824-w","relation":{},"ISSN":["1381-1991","1573-501X"],"issn-type":[{"value":"1381-1991","type":"print"},{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,24]]},"assertion":[{"value":"28 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors state that none of the work described in this manuscript appears to have been influenced by any known financial interests or personal relationships.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}